The British Journal of Cardiology

This site is intended for UK healthcare professionals

 
BJC_tv_logo_white
Sign in

Featured Videos

Amyloidosis overview – prevalence, pathophysiology and treatment approaches

Amyloidosis overview – prevalence, pathophysiology and treatment approaches

This Masterclass was developed in collaboration with the National Amyloidosis Centre, London UK

Amyloidosis is rapidly gaining recognition as a previously under-diagnosed cause of cardiomyopathy and heart failure. Here, experts from the National Amyloidosis Centre – the only centre in the UK specialising in the management of the condition – provide an overview of its prevalence, symptoms and key treatment principles.
Referral and diagnosis of suspected cardiac amyloidosis

Referral and diagnosis of suspected cardiac amyloidosis

This Masterclass was developed in collaboration with the National Amyloidosis Centre, London UK

Assessment of a patient with suspected amyloidosis requires a careful diagnostic workup, including cardiac imaging to identify amyloid infiltration in heart tissue that could lead to diastolic dysfunction and heart failure. In this Masterclass, clinicians and scientists from the National Amyloidosis Centre describe the laboratory tests and imaging techniques used to make an accurate diagnosis.
Amyloidosis signs and symptoms – red flags for cardiologists

Signs and symptoms of amyloidosis – red flags for cardiologists

This Masterclass was developed in collaboration with the National Amyloidosis Centre, London UK

Effective treatment of cardiac amyloidosis is dependent on early diagnosis; it is therefore important that clinicians have a high index of suspicion for the condition in their patients. Dr Josephine Mansell from the National Amyloidosis Centre outlines the “red flag” signs and symptoms that cardiologists, nurses or other healthcare professionals may observe in their patients, and which should prompt consideration of referral for a full diagnostic workup.

Urgent reversal of anticoagulants – lessons for practice

In recent years, there has been a switch to direct oral anticoagulants (DOACs) as first-line thrombosis prevention, with fewer people started on a vitamin K antagonist, such as warfarin. This has led to an increase in number of people taking anticoagulants and, therefore, an increased risk of intracranial and intracerebral haemorrhages and gastrointestinal bleeds. Listen to Richard Buka, Clinical Research Fellow Institute of Cardiovascular Sciences at the University of Birmingham, discuss the challenges clinical teams face in the reversal of these drugs. He explores the findings of recent trials of Andexanet alfa and considers how effective these drugs really are and what it means in practice.

The evolving role of a Cardio-oncology Clinical Nurse Specialist

The increasing survival rate of cancer patients along with the increase in the toxicity profile of treatments has resulted in a growing demand for specialist cardio-oncology care. Listen to Priya Reehal, Clinical Nurse Specialist at the Royal Brompton Hospital Centre of Excellence for Cardio-oncology, discuss her role, present the findings of a decade-long study into the number of patients referred for cancer therapy–related cardiac dysfunction, and explain why we need more cardio-oncology centres of excellence across the UK.

Cardiac inflammation: the fire within

Federica Marelli-Berg takes a look at some common and not-so-common causes of myocarditis, and the clinical manifestations cardiologists should consider.

Transcatheter cardiac valves: An update in 2024

Jon Byrne and Madalina Garbi explore the latest guidelines and current practice around transcatheter valve interventions (including aortic valve implantation (TAVI), mitral regurgitation management and tricuspid valve repair) – which patients are suitable for these interventions, and how do they compare to traditional surgical approaches?

Masterclass: Treating dyslipidaemia – special populations

In this masterclass, Alison Pottle and Jai Cegla provide discuss screening for familial hypercholesterolaemia (FH), treatment advances in dyslipidaemia, the role of lipid apheresis in specific populations and the importance of patient education.

© 2025 Medinews Cardiology Ltd, a wholly-owned subsidiary of OmniaMed Communications Ltd   |   Privacy & cookies policy   |   Terms & conditions

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.